AI-generated summary
The authors report a 12-month randomised, double-masked controlled trial of photobiomodulation in 138 eyes from 78 patients with early or intermediate dry age-related macular degeneration. Drusen volume decreased in the treatment group and increased in the sham group, and visual acuity improved more in the treatment group. The authors note that longer follow-up is needed to confirm any effect on disease progression.
- Participants
- 78
- Who or what was studied
- Patients with early or intermediate dry age-related macular degeneration (138 eyes from 78 patients)
- Limits stated in the abstract
- The abstract states that longer follow-up is needed to confirm whether photobiomodulation can slow the natural course of the disease.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on bjo.bmj.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Age-related macular degeneration, Sham, Primary outcome, Inflammation. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.